Pacific Biosciences of California (NASDAQ:PACB) Issues Quarterly Earnings Results

Pacific Biosciences of California (NASDAQ:PACB) released its earnings results on Wednesday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02, FiscalAI reports. The company had revenue of $40.56 million for the quarter, compared to analyst estimates of $43.82 million. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 82.49%.

Here are the key takeaways from Pacific Biosciences of California’s conference call:

• SPRQ-Nx adoption is expanding: it accounted for over half of Revio consumable revenue, and two-thirds of the install base had upgraded by quarter-end. PacBio expects adoption to broaden further and sees the lower cost per genome supporting higher utilization and stronger pull-through over time.
• Clinical genomics and strategic partnerships are gaining traction. Clinical consumables grew more than 20% year over year, while GeneDx plans to add long-read sequencing and Berry Genomics ordered 10 Revio systems for a five-year rare-disease program; PacBio also highlighted collaborations involving biomedical AI and drug discovery.
• Growth remains modest and uneven: Q3 revenue rose 6% year over year to $40.6 million, while consumables revenue fell year over year to $20.8 million as customers used existing inventory and validated new workflows. PacBio narrowed full-year revenue guidance to $155 million–$160 million and cited ongoing academic and government funding constraints.
• Gross margin declined to 36% from 42% a year earlier, with higher memory costs and Vega manufacturing transition costs weighing on results. The company ended the quarter with $199.4 million in cash, and management acknowledged that strategic deals will take time to translate into meaningful revenue and cash generation.
• PacBio said its high-throughput platform remains on track for commercial launch by the end of 2027, with development fully resourced. It continues to target cash-flow breakeven in 2028, citing planned expense reductions, although that goal depends on executing its product roadmap and growing revenue.

Pacific Biosciences of California Stock Up 4.5%

NASDAQ PACB traded up $0.11 on Wednesday, hitting $2.55. The company’s stock had a trading volume of 20,920,508 shares, compared to its average volume of 8,285,933. The firm has a market cap of $792.62 million, a PE ratio of -5.93 and a beta of 2.21. Pacific Biosciences of California has a 1-year low of $1.07 and a 1-year high of $3.43. The company’s 50-day moving average is $1.87 and its 200 day moving average is $1.62.

Insider Transactions at Pacific Biosciences of California

In related news, insider James Gibson, II sold 661,815 shares of Pacific Biosciences of California stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total value of $2,058,244.65. Following the transaction, the insider directly owned 1,083,848 shares of the company’s stock, valued at $3,370,767.28. The trade was a 37.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the transaction, the insider owned 2,705,853 shares in the company, valued at $3,057,613.89. This trade represents a 0.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

PACB has been the topic of several analyst reports. Wall Street Zen lowered shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. UBS Group initiated coverage on Pacific Biosciences of California in a research note on Wednesday, September 9th. They set a “neutral” rating and a $1.35 target price for the company. Finally, Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Pacific Biosciences of California has a consensus rating of “Reduce” and an average price target of $1.71.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.